Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism

References

• Büyükçelik A, Akbulut H. Thromboembolism in patients with cancer. Turk J Haematol. 2004;21(1):1.
   Google Scholar
• Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):S2–S9. doi:10.1038/sj.bjc.660559920386546
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fujino S, Inaba S, et al. Venous thromboembolism in patients with lung cancer. Clin Appl Thromb Hemost. 2020;26:1076029620977910. doi:10.1177/107602962097791033350315
   PubMed Web of Science ®Google Scholar
• Kushner A, West WP, Pillarisetty LS. Virchow triad. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 13, 2020.
   Google Scholar
• Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability. Cancers. 2020;12(3):566. doi:10.3390/cancers12030566
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi:10.1200/JCO.19.0146131381464
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM. Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. Thromb Res. 2020;191(Suppl 1):S79–S84. doi:10.1016/S0049-3848(20)30402-332736784
   PubMed Web of Science ®Google Scholar
• Pages P, Cottenet J, Mariet A, Bernard A, Quantin C. In-hospital mortality following lung cancer resection: nationwide administrative database. Eur Respir J. 2016;47(6):1809–1817. doi:10.1183/13993003.00052-201626965293
   PubMed Web of Science ®Google Scholar
• Maia R, Neves I, Morais A, Queiroga H. Venous and lung thromboembolism in the context of lung cancer: clinical manifestations, risk factors and prognosis. Acta Med Port. 2019;32(10):647‐653. doi:10.20344/amp.10260
   PubMed Web of Science ®Google Scholar
• Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131(1):24–30. doi:10.1016/j.thromres.2012.10.00723141849
   PubMed Web of Science ®Google Scholar
• Canale ML, Bisceglia I, Lestuzzi C, Parrini I; ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res. 2019;39(9):4619–4625. doi:10.21873/anticanres.1364231519559
   PubMed Web of Science ®Google Scholar
• Date K, Ettelaie C, Maraveyas A. Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. J Thromb Haemost. 2017;15(12):2289–2299. doi:10.1111/jth.1387129028284
   PubMed Web of Science ®Google Scholar
• Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 2011;127(5):473–477. doi:10.1016/j.thromres.2011.01.00221256535
   PubMed Web of Science ®Google Scholar
• Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med. 2007;13(5):362–367.17940477
   PubMed Web of Science ®Google Scholar
• Hsieh KY, Wei CK, Wu CC. YC-1 prevents tumor-associated tissue factor expression and procoagulant activity in hypoxic conditions by inhibiting p38/NF-κB signaling pathway. Int J Mol Sci. 2019;20(2):244. doi:10.3390/ijms20020244
   PubMed Web of Science ®Google Scholar
• Roselli M, Riondino S, Mariotti S, La Farina F, Ferroni P, Guadagni F. Clinical models and biochemical predictors of VTE in lung cancer. Cancer Metastasis Rev. 2014;33(2–3):771–789. doi:10.1007/s10555-014-9500-x24748012
   PubMed Web of Science ®Google Scholar
• Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6(4):601–608. doi:10.1111/j.1538-7836.2008.02908.x18208538
   PubMed Web of Science ®Google Scholar
• Bigay-Gamé L, Bota S, Greillier L, et al.; GFPC Investigators. Characteristics of lung cancer in patients younger than 40 years: a prospective multicenter analysis in France. Oncology. 2018;95(6):337–343. doi:10.1159/00048978430278447
   PubMed Web of Science ®Google Scholar
• Konigsbrugge O, Lotsch F, Reitter EM, et al. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. J Thromb Haemost. 2013;11(11):1993–2000. doi:10.1111/jth.1240824112869
   PubMed Web of Science ®Google Scholar
• Liu Y, Gu Y, Yi F, Cao B. [Retrospective analysis of risk factors for venous thromboembolism in 283 patients with lung cancer during systemic therapy]. Zhongguo Fei Ai Za Zhi. 2019;22(7):419–426. Chinese31315780
   PubMedGoogle Scholar
• Zhang Y, Yang Y, Chen W, et al. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Sci Rep. 2016;6(1):19603. doi:10.1038/srep1960326797411
   PubMed Web of Science ®Google Scholar
• Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018;35(5):1. doi:10.1007/s12032-018-1120-9
   Web of Science ®Google Scholar
• Zer A, Moskovitz M, Hwang DM, et al. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer. 2017;18(2):156–161. doi:10.1016/j.cllc.2016.10.00727913214
   PubMed Web of Science ®Google Scholar
• Murray PB, Lax I, Reshetnyak A, et al. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal. 2015;8(360):360. doi:10.1126/scisignal.2005916
   Web of Science ®Google Scholar
• Corrales-Rodriguez L, Soulieres D, Weng X, Tehfe M, Florescu M, Blais N. Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study. Thromb Res. 2014;133(1):48–51. doi:10.1016/j.thromres.2013.10.04224290524
   PubMed Web of Science ®Google Scholar
• Chiari R, Ricciuti B, Landi L, et al. ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a Phase II, prospective, multicenter, two-arms trial (METROS). Clin Lung Cancer. 2020;21(1):15–20. doi:10.1016/j.cllc.2019.06.01231607443
   PubMed Web of Science ®Google Scholar
• Walker AJ, Baldwin DR, Card TR, Powell HA, Hubbard RB, Grainge MJ. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. Br J Cancer. 2016;115(1):115–121. doi:10.1038/bjc.2016.14327253177
   PubMed Web of Science ®Google Scholar
• Zhang M, Wu S, Hu C. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. J Int Med Res. 2020;48(1):300060519896919.31948304
   PubMed Web of Science ®Google Scholar
• Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2012;30(31):3870–3875. doi:10.1200/JCO.2011.40.181023008313
   PubMed Web of Science ®Google Scholar
• Dickmann B, Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica. 2013;98(8):1309–1314. doi:10.3324/haematol.2012.07333823585523
   PubMed Web of Science ®Google Scholar
• Chin CG, Yeh JS, Lin YK, Tam WC. Superior vena cava syndrome complicated with acute pulmonary thromboembolism in a patient with lung cancer. J Cardiol Cases. 2018;17(1):9–11. doi:10.1016/j.jccase.2017.08.00430279843
   PubMedGoogle Scholar
• Xu C, Fu X. [The changes of blood coagulation in surgical patients with lung cancer]. Zhongguo Fei Ai Za Zhi. 2010;13(2):136–139. Chinese.20673507
   PubMedGoogle Scholar
• Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016;151(1):37–44.e1. doi:10.1016/j.jtcvs.2015.08.03926386868
   PubMed Web of Science ®Google Scholar
• Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466–3473. doi:10.1200/JCO.2011.35.566921810688
   PubMed Web of Science ®Google Scholar
• Salla E, Dimakakos EP, Tsagkouli S, et al. Venous thromboembolism in patients diagnosed with lung cancer. Angiology. 2016;67(8):709–724. doi:10.1177/000331971561494526553057
   PubMed Web of Science ®Google Scholar
• Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013;382(9889):311–325. doi:10.1016/S0140-6736(13)60592-923697825
   PubMed Web of Science ®Google Scholar
• Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012;13(6):482–487. doi:10.1016/j.cllc.2012.03.00522591606
   PubMed Web of Science ®Google Scholar
• Gong CY, Li ZW, Zhou DX, et al. [Risk factors of lung cancer complicated with symptomatic venous thromboembolism]. Zhonghua Jie He He hu Xi Za Zhi. 2016;39(6):454–458. Chinese.27289575
   PubMedGoogle Scholar
• Kadlec B, Skrickova J, Merta Z, Dusek L, Jarkovsky J. The incidence and predictors of thromboembolic events in patients with lung cancer. Sci World J. 2014;2014:125706. doi:10.1155/2014/125706
   Web of Science ®Google Scholar
• Bai Y, Chen H. [Biomarkers and risk assessment scores for prediction of chemotherapy-associated venous thromboembolism in lung cancer patients]. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38(10):767–769. Chinese.26703946
   PubMedGoogle Scholar
• Vitale C, D’Amato M, Calabro P, Stanziola AA, Mormile M, Molino A. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med. 2015;10(1):28. doi:10.1186/s40248-015-0021-426380084
   PubMedGoogle Scholar
• Anghel L, Sascau R, Radu R, Statescu C. From classical laboratory parameters to novel biomarkers for the diagnosis of Venous Thrombosis. Int J Mol Sci. 2020;21(6):1920. doi:10.3390/ijms21061920
   PubMed Web of Science ®Google Scholar
• Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703–2708. doi:10.1182/blood-2008-02-14242218539899
   PubMed Web of Science ®Google Scholar
• Ferroni P, Riondino S, Formica V, et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer. 2015;136(5):1234–1240. doi:10.1002/ijc.2907625042739
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907. doi:10.1182/blood-2007-10-11632718216292
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773–1778. doi:10.1111/jth.1337827273134
   PubMed Web of Science ®Google Scholar
• Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost. 2012;108(6):1042–1048.22836491
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97(8):1158–1164. doi:10.3324/haematol.2011.05471822371182
   PubMed Web of Science ®Google Scholar
• Königsbrügge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res. 2014;133(Suppl 2):S39–S43. doi:10.1016/S0049-3848(14)50007-224862144
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382. doi:10.1182/blood-2010-02-27011620829374
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017;102(9):1494–1501. doi:10.3324/haematol.2017.16906028550192
   PubMed Web of Science ®Google Scholar
• Cella CA, Di Minno G, Carlomagno C, et al. Preventing Venous Thromboembolism in ambulatory cancer patients: the ONKOTEV Study. Oncologist. 2017;22(5):601–608. doi:10.1634/theoncologist.2016-024628424324
   PubMed Web of Science ®Google Scholar
• Godinho J, Casa-Nova M, Moreira-Pinto J, et al. ONKOTEV score as a predictive tool for thromboembolic events in pancreatic cancer–A retrospective analysis. Oncologist. 2019;25(2):e284.32043787
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Eldredge JB, Anand LN, et al. External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model. Oncologist 2020;25(7):e1083–e1090. doi:10.1634/theoncologist.2019-048232017293
   PubMed Web of Science ®Google Scholar
• Muñoz Martín AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(8):1056–1061. doi:10.1038/s41416-018-0027-829588512
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncologist. 2018;23(2):247‐255. doi:10.1634/theoncologist.2017-0205
   PubMed Web of Science ®Google Scholar
• Hakoum MB, Kahale LA, Tsolakian IG, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;1(1):CD006649.29363105
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Skalij P, Tokajuk P, et al. Direct oral anticoagulants in cancer patients. Time for a change in paradigm. Cancers. 2020;12(5):E1144. doi:10.3390/cancers1205114432370207
   PubMed Web of Science ®Google Scholar
• Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017;2(2):CD001100.28182249
   PubMed Web of Science ®Google Scholar
• Howlett J, Benzenine E, Fagnoni P, Quantin C. Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management? J Thromb Thrombolysis. 2020;50(3):642–651. doi:10.1007/s11239-020-02047-132020515
   PubMed Web of Science ®Google Scholar
• Rhea IB, Lyon AR, Fradley MG. Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies. Curr Oncol Rep. 2019;21(5):45. doi:10.1007/s11912-019-0797-z30949848
   PubMed Web of Science ®Google Scholar
• Khalil L, Wong HS, Keeling DM, Desborough MJ. Venous thromboembolism: risk of recurrence and long-term anticoagulation. Br J Hosp Med. 2015;76(2):72–77. doi:10.12968/hmed.2015.76.2.72
   Web of Science ®Google Scholar
• Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. J Natl Cancer Center. 2021;1(1):2–11. doi:10.1016/j.jncc.2020.12.001
   Google Scholar
• Orly L, Connors Jean M, Hanny A-S. Impact of tumor genomic mutations on Thrombotic risk in cancer patients. Cancers. 2020;12:1958.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhao H, Zhao Q, et al. Risk factors and clinical significance of D-dimer in the development of postoperative venous thrombosis in patients with lung tumor. Cancer Manag Res. 2020;12:5169–5179. doi:10.2147/CMAR.S25648432636679
   PubMed Web of Science ®Google Scholar